Oct 27, 2026 7:00am EDT Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
Oct 26, 2026 7:00am EDT Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026
Oct 19, 2026 7:00am EDT Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA® at the IASP 2026 World Congress on Pain
Oct 15, 2026 7:00am EDT Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
Sep 22, 2026 7:00am EDT Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Sep 8, 2026 7:00am EDT Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Sep 2, 2026 7:00am EDT Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
Aug 10, 2026 7:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Aug 3, 2026 7:00am EDT Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
